ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
86
86
0
7
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
17,802
27,245
22,806
16,785
Selling General and Administrative
13,234
13,239
10,017
6,430
Total Operating Expenses
31,036
40,484
32,823
23,215
Operating Income or Loss
-30,950
-40,398
-32,823
-23,208
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-618
-475
291
-289
Income Before Tax
-30,019
-39,911
-32,012
-23,416
Income Tax Expense
-
0
0
-28
Income from Continuing Operations
-30,019
-39,911
-32,012
-23,389
Net Income
-30,019
-39,911
-32,012
-23,389
Net Income available to common shareholders
-30,019
-39,911
-32,012
-23,389
Reported EPS
Basic
-
-2.61
-2.48
-2.58
Diluted
-
-2.61
-2.48
-2.58
Weighted average shares outstanding
Basic
-
15,309
12,915
9,070
Diluted
-
15,309
12,915
9,070
EBITDA
-
-40,398
-32,823
-23,208